Acquisition of numerous patents based on BMS original know-how and technologies

Our core cell culture media technology is protected as know-how, since there are many risks involved in disclosing the composition of media.

For the above reasons, the major patents we holds are for use (patents with rights limited by the target disease) or are on manufacturing methods. Among these patents, there are rights regarding MSC being an agent that regulates diseases or gene expression, protein expression, and function associated with a disease. We plan to expand these rights to a variety of diseases. These patents can be licensed out and, accordingly, we are open to discussion at any time.

In the future, the composition of media may be subject to rights in the course of development for disease-specific media. In such circumstances, we plan to make a final decision on the acceptability of applications in consultation with companies/organizations that are interested in the media.